FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2603044980> ?p ?o ?g. }

• W2603044980 endingPage "8544" @default.
• W2603044980 startingPage "8544" @default.
• W2603044980 abstract "8544 Background: The GHSG HD9 trial had established BEACOPP escalated (BE) as new standard of care for advanced-stage HL patients. The successor study, HD12, evaluated a possible reduction in toxicity by comparing 8 cycles of BE with 4 cycles BE followed by 4 cycles BB. The second question in this trial related to the need of additional radiotherapy (RT) to initial bulk and residual disease. Methods: HL patients in stage IIB with large mediastinal mass and/or E-lesions or stage III/IV were randomised according to a 2x2-factorial design between: 8BE + RT, 8BE no RT, 4BE+4BB + RT, 4BE+4BB no RT. Primary endpoint of the trial was FFTF. Between 9/1999 and 1/2003, a total of 1,670 patients aged 16–65 were randomized. For this final analysis at a median follow up of 78 months, 99 patients were excluded for various reasons resulting in 1,571 eligible patients. Results: Patient characteristics in the 4 groups were comparable. Treatment-related toxicity of WHO grade III/IV was observed in 97% of patients. Most prominent differences between pooled chemotherapy arms were anemia (65% 8BE vs 51% 4BE+4BB) and thrombopenia (65% vs 51%). Treatment outcome: complete remission 92.4%; early progression 2.2%; progression/relapse 7.8% (6.6% and 8.5%). A total of 156 (9.9%) deaths (72 vs 84) have been observed (22 vs 32 acute or salvage treatment toxicity; 15 vs 24 HL; 22 vs 13 secondary neoplasia). Most treatment related deaths occurred in the >60 years age group, the first 4 cycles and the IPS> 3 RF groups. Secondary neoplasias were observed in 77 patients (4.9%). At 5 years, OS was 91%, FFTF 85.5% and progression free survival (PFS) 86.2% (Kaplan-Meier estimates). Estimates for the difference at 5 years are 1.8% for OS, 2.3% for FFTF and 2.7% for PFS favoring BE. However, there was no statistical difference between 8x BE and 4BE+4BB in all outcome parameters (p>0.19, log rank test). There is also no significant difference between the RT or no-RT arms in this study. Conclusions: The adoption of 4BE+4BB as a new standard in the future GHSG studies will depend on a refined analysis of the total data set and will be presented. No significant financial relationships to disclose." @default.
• W2603044980 created "2017-04-07" @default.
• W2603044980 creator A5000800777 @default.
• W2603044980 creator A5004418060 @default.
• W2603044980 creator A5039994927 @default.
• W2603044980 creator A5040300122 @default.
• W2603044980 creator A5046696083 @default.
• W2603044980 creator A5057387418 @default.
• W2603044980 creator A5066624700 @default.
• W2603044980 creator A5071950409 @default.
• W2603044980 creator A5074749665 @default.
• W2603044980 creator A5087532681 @default.
• W2603044980 date "2009-05-20" @default.
• W2603044980 modified "2023-10-16" @default.
• W2603044980 title "Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients in advanced stage Hodgkin lymphoma (HL): Final analysis of the HD12 trial of the German Hodgkin Study Group (GHSG)" @default.
• W2603044980 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.8544" @default.
• W2603044980 hasPublicationYear "2009" @default.
• W2603044980 type Work @default.
• W2603044980 sameAs 2603044980 @default.
• W2603044980 citedByCount "10" @default.
• W2603044980 countsByYear W26030449802012 @default.
• W2603044980 countsByYear W26030449802014 @default.
• W2603044980 countsByYear W26030449802016 @default.
• W2603044980 countsByYear W26030449802018 @default.
• W2603044980 crossrefType "journal-article" @default.
• W2603044980 hasAuthorship W2603044980A5000800777 @default.
• W2603044980 hasAuthorship W2603044980A5004418060 @default.
• W2603044980 hasAuthorship W2603044980A5039994927 @default.
• W2603044980 hasAuthorship W2603044980A5040300122 @default.
• W2603044980 hasAuthorship W2603044980A5046696083 @default.
• W2603044980 hasAuthorship W2603044980A5057387418 @default.
• W2603044980 hasAuthorship W2603044980A5066624700 @default.
• W2603044980 hasAuthorship W2603044980A5071950409 @default.
• W2603044980 hasAuthorship W2603044980A5074749665 @default.
• W2603044980 hasAuthorship W2603044980A5087532681 @default.
• W2603044980 hasConcept C126322002 @default.
• W2603044980 hasConcept C126894567 @default.
• W2603044980 hasConcept C141071460 @default.
• W2603044980 hasConcept C146357865 @default.
• W2603044980 hasConcept C151730666 @default.
• W2603044980 hasConcept C168563851 @default.
• W2603044980 hasConcept C203092338 @default.
• W2603044980 hasConcept C2776694085 @default.
• W2603044980 hasConcept C29730261 @default.
• W2603044980 hasConcept C2989005 @default.
• W2603044980 hasConcept C509974204 @default.
• W2603044980 hasConcept C71924100 @default.
• W2603044980 hasConcept C86803240 @default.
• W2603044980 hasConcept C90924648 @default.
• W2603044980 hasConceptScore W2603044980C126322002 @default.
• W2603044980 hasConceptScore W2603044980C126894567 @default.
• W2603044980 hasConceptScore W2603044980C141071460 @default.
• W2603044980 hasConceptScore W2603044980C146357865 @default.
• W2603044980 hasConceptScore W2603044980C151730666 @default.
• W2603044980 hasConceptScore W2603044980C168563851 @default.
• W2603044980 hasConceptScore W2603044980C203092338 @default.
• W2603044980 hasConceptScore W2603044980C2776694085 @default.
• W2603044980 hasConceptScore W2603044980C29730261 @default.
• W2603044980 hasConceptScore W2603044980C2989005 @default.
• W2603044980 hasConceptScore W2603044980C509974204 @default.
• W2603044980 hasConceptScore W2603044980C71924100 @default.
• W2603044980 hasConceptScore W2603044980C86803240 @default.
• W2603044980 hasConceptScore W2603044980C90924648 @default.
• W2603044980 hasIssue "15_suppl" @default.
• W2603044980 hasLocation W26030449801 @default.
• W2603044980 hasOpenAccess W2603044980 @default.
• W2603044980 hasPrimaryLocation W26030449801 @default.
• W2603044980 hasRelatedWork W1535958986 @default.
• W2603044980 hasRelatedWork W2003938723 @default.
• W2603044980 hasRelatedWork W2047967234 @default.
• W2603044980 hasRelatedWork W2118496982 @default.
• W2603044980 hasRelatedWork W2376593068 @default.
• W2603044980 hasRelatedWork W2390264150 @default.
• W2603044980 hasRelatedWork W2439875401 @default.
• W2603044980 hasRelatedWork W4220939315 @default.
• W2603044980 hasRelatedWork W4238867864 @default.
• W2603044980 hasRelatedWork W2525756941 @default.
• W2603044980 hasVolume "27" @default.
• W2603044980 isParatext "false" @default.
• W2603044980 isRetracted "false" @default.
• W2603044980 magId "2603044980" @default.
• W2603044980 workType "article" @default.